An advanced skin cancer therapy that combines immunotherapy with mRNA vaccine technology has shown promising outcomes in a late-stage trial, according to pharmaceutical giants Merck and Moderna. The treatment, known as intismeran, outperformed standard immunotherapy in reducing melanoma recurrence and containing cancer spread in patients who had undergone prior melanoma surgery.
The announcement described the results as statistically significant and clinically meaningful. However, medical professionals remain cautiously optimistic as the Phase 3 trial is ongoing, with the disclosed results being from an interim analysis. The companies plan to present detailed data at an upcoming oncology conference and to regulatory bodies.
Dr. Marcus Butler, an expert in medical oncology at Toronto’s Princess Margaret Cancer Centre, expressed excitement over the development, citing the positive outcomes seen in a smaller Phase 2 study. He emphasized the need for further validation and noted that the treatment’s availability to Canadians may be more than eight months away pending trial completion.
The therapy integrates Merck’s pembrolizumab immunotherapy drug with a personalized mRNA vaccine from Moderna, tailored to target specific mutations found in each patient’s tumors. Pembrolizumab boosts the immune system by removing inhibitory signals, while mRNA vaccines instruct cells to aid the immune system in combating cancer cells.
Dr. Lennard Lee, a medical oncologist and associate professor, explained that the therapy utilizes tumor samples to identify abnormal proteins in cancer cells, called neoantigens. An individualized mRNA vaccine derived from the patient’s tumor samples trains the immune system to recognize and attack cancer cells carrying these antigens.
While the trial enrolled over a thousand high-risk melanoma patients, including Canadians, concerns exist about potential immune system stimulation from mRNA vaccines unrelated to melanoma treatment. The study lacked a placebo group receiving a dummy vaccine, potentially complicating the interpretation of results.
Dr. Butler cautioned that the trial’s focus was limited to early-stage melanoma patients with completely removed tumors. Ongoing studies are exploring the therapy’s effectiveness in later-stage melanoma, as past trials have shown mixed results. Further research is needed to determine the therapy’s efficacy across different melanoma stages.